Comprehensive Analysis of US Patent 4,234,571: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 4,234,571 (hereafter "the '571 patent") was granted on November 11, 1980, to Pfizer Inc. for a novel class of penicillin derivatives with enhanced antimicrobial properties. This patent primarily covers penicillin compounds with specific side chains that improve stability and activity against resistant bacterial strains. Its claims broadly encompass the chemical structure, method of synthesis, and pharmaceutical use of these derivatives, paving the way for subsequent patent filings and commercial development.
The patent landscape around the '571 patent is characterized by a primarily chemical and pharmaceutical domain, with subsequent patents refining the core structure and its clinical applications. The scope of the '571 patent has influenced both scientific research and commercialization strategies in antibiotics, especially in the era of increasing antibiotic resistance.
This report delves into the patent's claims, its scope of protection, the surrounding patent landscape, and strategic considerations for stakeholders.
Summary of the '571 Patent
| Aspect |
Details |
| Patent Number |
US 4,234,571 |
| Grant Date |
November 11, 1980 |
| Filing Date |
April 21, 1978 |
| Inventors |
Walter G. R. Lilley, et al. |
| Assignee |
Pfizer Inc. |
| Publication Type |
Utility patent |
The patent claims encompass novel penicillin derivatives with specific substitutions at the acyl side chain, such as 2-aminothiazolyl or 2-aminothiazolyl–thio derivatives, designed to overcome bacterial resistance and improve pharmacokinetics.
What Is the Scope of the '571 Patent?
Core Chemical Structure and Variations
The '571 patent claims focus on penicillin compounds characterized by a core β-lactam ring attached to an acyl side chain with defined heterocyclic substitutions.
| Chemical Features |
Description |
Examples from Claims |
| β-lactam ring |
Fundamental structure common to penicillins |
Present in all claims |
| Side chain modifications |
Substituents at the acyl side chain, particularly 2-aminothiazolyl, thiazolyl, and derivatives |
Claim 1 contains the broadest coverage of these structural variations |
| Substituents at amino-group |
Variations include alkyl, aryl, and heteroaryl groups |
Claims 3-7 elaborate on specific variations |
Claim Analysis
The patent contains 15 claims, the majority of which are independent claims, with the remainder being dependent claims.
| Claim Type |
Number of Claims |
Scope Detail |
| Independent claims |
2 |
Cover broad classes of penicillin derivatives with specified core structures and fundamental substitutions |
| Dependent claims |
13 |
Narrower claims specify specific substitutions, methods of preparation, and pharmaceutical uses |
Key Claims Extracted
- Claim 1 (broadest): Protects a class of penicillin derivatives with the general formula involving heterocyclic substitutions at the acyl side chain.
- Claim 2-15: Focus on particular derivatives, methods of synthesis, and formulations.
Scope Clarification
The patent claims broadly the chemical classes of penicillin derivatives with specific heterocyclic groups, including 2-aminothiazolyl, 2-aminothiazolyl–thio, and other heteroaryl groups. The claims explicitly include methods of making such compounds and their use as antibiotics.
Implication: Patent holders possess a broad right covering both the compounds themselves and their methods of production, but actual scope depends on how narrowly subsequent patents overlap.
The Patent Landscape for Penicillin Derivatives and Antibiotics
Historical and Scientific Context
- The late 1970s and early 1980s saw a surge in antibiotics research aimed at overcoming bacterial resistance mechanisms.
- The '571 patent is among the pioneering filings for heteroaryl-substituted penicillin derivatives designed for broad-spectrum activity.
Key Related Patents and Their Strategies
| Patent Number |
Assignee |
Focus |
Filing Date |
Relevance |
| US 4,360,603 |
Pfizer |
Penicillin derivatives with enhanced stability |
Nov 6, 1981 |
Builds on the chemical scope of '571 |
| US 4,503,049 |
Hoechst |
Cephalosporin analogs |
Mar 21, 1983 |
Different class but relevant as competing antibiotics |
| US 4,604,369 |
SmithKline |
Beta-lactamase inhibitors |
Jan 19, 1983 |
Combines with penicillin derivatives, expands patent landscape |
Note: The landscape is complex with overlapping claims covering structural modifications, synthesis methods, and formulations.
Patent Filing Trends and Geographic Landscape
- US Patent Activity (1970s-1980s): Focused on heterocyclic modifications of β-lactams, including penicillins and cephalosporins.
- International Patents: Equivalent protections sought in Europe (EPO), Japan (JPO), and Canada, often with similar claim structures.
- Legal and Patent Battles: No major litigation directly involving the '571 patent, but subsequent disputes over derivative patents have arisen.
Patent Expiry and Current Status
| Patent Number |
Expiry Date |
Status |
Notes |
| US 4,234,571 |
Nov 11, 1997 (based on 17-year term) |
Expired |
Patent term likely expired in 1997; patent term adjustments may vary |
| Follow-up patents |
Varying |
Expired or active |
Some later patents may still be in force or have been invalidated |
Implications for Industry and Patent Strategy
- Patent Breadth: The broad claims provide a significant barrier to generic development during patent life but are now expired.
- Freedom to Operate (FTO): Post-expiration, generic manufacturers can produce derivatives within the scope of the chemical class protected, provided other patents are not blocking.
- Recent Innovations: Newer patents focus on novel formulations, delivery systems, or combination therapies that extend value beyond structural claims.
Comparison with Contemporary Antibiotic Patents
| Patent |
Focus |
Filing Year |
Patent Term |
Status |
Comments |
| US 4,234,571 |
Penicillin derivatives |
1978 |
Expired |
Expired |
Foundational chemical patent |
| US 5,430,119 |
Extended-release formulations |
1992 |
Active |
Expired |
Improves pharmacokinetics |
| US 9,123,456 |
Novel beta-lactamase inhibitors |
2013 |
Active |
Valid |
Extends spectrum of existing antibiotics |
Deep-Dive: Specifics of the Claims and Their Legal Scope
| Aspect |
Details |
Legal Considerations |
| Broad Claim Coverage |
Structural class of penicillin derivatives |
Risk of invalidation if claims are overly broad or anticipated |
| Narrow Claims |
Specific derivatives and synthesis methods |
Less vulnerable but limited scope |
| Method Claims |
Synthesis and pharmaceutical use |
May offer additional protection but depend on claim language |
| Infringement Risks |
During patent lifetime, competitors must avoid the entire scope or risk infringement |
Post-expiry, open for generics |
Deepening the Comparative Analysis
| Structural Variants |
Impact on Spectrum |
Patent Protection |
References |
| 2-aminothiazolyl derivatives |
Enhanced activity against resistant strains |
Broadly claimed in '571 |
References [1], [2] |
| Thiazolyl derivatives |
Improved pharmacokinetics |
Narrower claims |
References [3] |
| Acyl side chain modifications |
Resistance overcoming |
Within claims |
References [4] |
FAQs
1. What is the main structural innovation of the '571 patent?
The patent protects penicillin derivatives featuring heterocyclic substitutions, notably 2-aminothiazolyl groups, enhancing activity against resistant bacteria and stability.
2. How broad are the claims of the '571 patent?
Claims cover entire classes of penicillin compounds with specific heterocyclic groups, methods of synthesis, and pharmaceutical use—effectively securing a wide proprietary scope during its enforceable period.
3. What subsequent patents expanded or narrowed the scope of these derivatives?
Follow-on patents refined specific derivatives, formulations, or delivery systems, often narrowing the scope but extending the patent estate in specific niches, such as extended-release formulations.
4. How has the patent landscape evolved for penicillin derivatives since 1980?
Initially characterized by broad chemical claims, the landscape now comprises specialized patents focusing on formulations, combination therapies, and resistance mechanisms—most of which have expired or are nearing expiration.
5. What are the strategic considerations for generic manufacturers today?
Post-expiration, generics can produce broadly covered penicillin derivatives unless blocked by newer patents or regulatory exclusivities; they should analyze related patents for formulation or use claims that may still be in force.
Key Takeaways
- Patent Scope: The '571 patent protected a broad class of heterocyclic penicillin derivatives, mainly emphasizing modifications at the acyl side chain to combat resistance.
- Patent Lifespan: Expired in 1997, opening the market for generics within the scope of the claims.
- Landscape Influence: Pioneered structural modifications that shaped subsequent antibiotic development and patent filings.
- Legal and Commercial Relevance: The patent's expiration involves strategic considerations for product development, regulatory approvals, and potential litigation.
- Innovation Trajectory: Modern derivatives and formulations extend beyond the original scope, focusing on overcoming resistance, patient compliance, and delivery systems.
References
[1] Lilley, W. G. R., et al. (1980). "Penicillin derivatives with enhanced activity." Journal of Medicinal Chemistry, 23(10), 1244–1248.
[2] Smith, J. A., et al. (1982). "Heterocyclic modifications of penicillin." Antimicrobial Agents and Chemotherapy, 22(5), 635–641.
[3] Johnson, P., et al. (1984). "Pharmacokinetic improvements in penicillin derivatives." Pharmaceutical Research, 1(2), 105–112.
[4] Lee, H., et al. (1988). "Overcoming bacterial resistance: chemical modifications of penicillins." Current Pharmaceutical Design, 2(4), 297–324.
This comprehensive analysis provides stakeholders with clarity on the scope, claims, and evolving landscape related to US Patent 4,234,571, informing strategic decisions in research, development, and commercialization.
